查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401849

2030 年药物研发发现市场预测的药物化学：按工艺、设计、药物类型、治疗领域、最终用户和地区进行的全球分析

Medicinal Chemistry For Drug Discovery Market Forecasts to 2030 - Global Analysis By Process, Design, Drug Type, Therapeutic Area, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，到 2023 年，药物研发市场将达到 925 亿美元，预计在预测期内将以 13.5% 的复合年增长率增长，到 2030 年将达到 2,244.5 亿美元。

用于药物药物研发的药物化学是一个跨学科领域，结合了化学、生物学和药理学原理来设计和开发新的药物化合物。其目的是识别和优化具有治疗潜力的分子，同时考虑安全性、有效性和作用机制等因素，最终创造出治疗疾病的新药。

根据世界卫生组织 (WHO) 统计，每年有近 1800 万人死于心血管疾病，使其成为全球第一大死因。

扩大医疗设施

医疗保健基础设施的扩展和可近性增加了对新製药解决方案的需求。此次扩建包括建立新的医院、诊所和研究中心，为临床和药物试验提供平台。此外，改善的医疗设施将加强患者护理，并改善各种医疗状况的诊断和治疗。此外，设施扩建将透过吸引公共和私营部门的投资、支持研究以及促进製药公司和医疗机构之间的合作，加速新药的发现和发展。

开发成本上升

新药从发现到核准的过程需要资本密集的过程，包括临床前测试、广泛的临床试验和监管集中。这些成本包括研究、人员、基础设施以及遵守严格的安全性和有效性标准。这些成本的经济负担可能会阻碍对潜在致命的候选药物的投资，限制获得先进治疗方法的机会，并最终阻碍该领域的进展，延迟为患者提供新的治疗方法。

整合数位健康和​​人工智慧

人工智慧和数位健康技术使药物研究人员能够处理大量资料集，加速潜在候选药物的识别并预测其在生物系统中的行为。机器学习演算法可以透过分析分子结构和识别药物-标靶相互作用来简化先导化合物优化过程。这些技术还将支持远端患者监护和真实世界证据生成，以改善药物安全性和疗效评估。人工智慧与数位健康之间的协同效应不仅将加速药物研发，还将带来更个体化和有效的治疗，为製药业带来重大投资和创新。因此，这些技术正在推动市场成长。

故障率高

由于安全问题、无效和意想不到的副作用，大多数潜在的药物组合从未进入市场。药物开发过程受到不确定性的困扰。此外，此类失败可能会为製药公司带来重大财务损失，并阻碍研究投资。在不成功的药物上花费大量时间和资源会阻碍技术创新并限制新治疗方法的获得，最终解决未满足的医疗需求并改善患者的治疗结果。这将削弱製药业的能力。

COVID-19 的影响

COVID-19大流行对药物研发的药物化学市场产生了重大影响。在加速 COVID-19 治疗和疫苗研究的同时，它扰乱了非 COVID-19 药物的开发，导致资源的延迟和重新分配。封锁影响了实验室工作和临床试验。协作和资料共用有所增加，以促进研究。监管机构也进行了调整併加快了核准。长期影响包括研究重点的转变，重点放在疫苗开发和抗病毒疗法上，以及重新关注全球卫生安全。

生技药品产业预计将在预测期内成为最大的产业

生技药品产业估计占最大占有率。生技药品是从生物资源中提取的一类药物。单株抗体、蛋白质和核酸等复杂分子是治疗药物开发的重点。生物製药旨在高精确度针对特定疾病途径，为多种疾病提供有效的治疗方法，包括自体免疫疾病、癌症和罕见疾病。此外，生技药品的开发涉及复杂的药物化学、基因工程和生物技术。生物製药正在彻底改变医疗保健，提供创新且经常改变生活的治疗选择，并且是製药业快速成长和发展的一部分。

肿瘤学领域预计在预测期内复合年增长率最高

预计肿瘤学领域在预测期内将出现良好的成长。肿瘤学是医学和医学科学的一个分支，专注于发现和开髮用于诊断、预防和治疗各种癌症的专用药物。癌症的盛行率和复杂性使其成为一个重要的研究领域。肿瘤学领域的药物化学家设计和优化针对癌细胞、破坏疾病途径并增强人体抗癌能力的分子。此外，这些治疗方法包括传统化疗、标靶治疗、免疫疗法和新方法，推动不断创新，以应对世界上最具挑战性的健康问题。

占有率最大的地区

在估计期间，亚太地区占据最大的市场占有率。亚太地区在药物研发的药物化学市场中扮演重要角色。亚太地区包括许多医疗基础设施和研究能力不断增强的国家。中国、印度、日本和韩国是药物研究和製造的主要中心。该地区受益于较低的研究成本，并吸引了全球製药公司的投资。此外，亚太地区是全球药物化学药物研发市场中充满活力且重要的部分，为接触广大患者群体进行合作研究、临床试验和新药试验提供了机会。我是。

复合年增长率最高的地区：

预计北美在预测期内将实现盈利成长。美国和加拿大是许多大型製药企业、知名研究机构和强大的医疗基础设施的所在地，是专注于基因组学和生技药品等最尖端科技的创新中心。此外，该地区受益于强有力的智慧财产权保护，促进了药物开发和商业化。北美继续处于药物研发的前沿，经常设定药物研究和开发的全球趋势和标准。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章药物研发的全球药物化学市场：依流程

  • 目标选择
  • 候选人检验
  • 点选读取识别
  • 潜在客户优化

第六章药物研发的全球药物化学市场：设计

  • 基于片段的变化
  • 面向多样性的综合
  • 基于结构的药物设计
  • 天然产物
  • 化学基因体学
  • 其他设计

第七章按药物类型药物研发的全球药物化学市场

  • 生技药品
  • 低分子

第八章药物研发的全球药物化学市场：按治疗领域

  • 肿瘤学
  • 感染疾病和免疫系统疾病
  • 神经病学
  • 消化器官系统疾病
  • 心血管疾病
  • 其他治疗领域

第九章药物研发的全球药物化学市场：按最终用户分类

  • 合约研究组织
  • 学术研究所
  • 製药和生物技术公司
  • 其他最终用户

第十章全球药物研发化学市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Eurofins Scientific
  • WuXi Apptec
  • Labcorp Drug Development
  • Charles River
  • Evotec SE
  • Charles River
  • Piramal Pharma Solutions
  • Certara USA
  • Pfizer, Inc.
  • Sygnature Discovery Limited
  • Jubilant Biosys Ltd.
  • Malvern Panalytical Ltd
  • Taros Chemicals GmbH & Co. KG
  • Nereid Therapeutics Inc.
  • Genscript Biotech Corporation
  • BioBlocks, Inc.
  • Domainex
  • Aurelia Biosciences Ltd.
  • Thermo Fisher Scientific Inc.
  • Spectris Plc
Product Code: SMRC24369

According to Stratistics MRC, the Global Medicinal Chemistry For Drug Discovery Market is accounted for $92.50 billion in 2023 and is expected to reach $224.45 billion by 2030 growing at a CAGR of 13.5% during the forecast period. Medicinal chemistry for drug discovery is a multidisciplinary field that combines principles of chemistry, biology, and pharmacology to design and develop new pharmaceutical compounds. It aims to identify and optimise molecules with therapeutic potential, considering factors such as safety, efficacy, and mechanism of action, ultimately leading to the creation of novel drugs for the treatment of diseases.

According to the World Health Organization, the cardiovascular diseases results in almost 18 million deaths each year and it is the leading cause of death across the globe.

Market Dynamics:

Driver:

Expanding healthcare facilities

The expanding and improved accessibility of healthcare infrastructure raises the need for novel pharmaceutical solutions. This expansion includes the establishment of new hospitals, clinics, and research centres, providing a platform for clinical trials and drug testing. Additionally, improved healthcare facilities enhance patient care, leading to greater diagnosis and treatment of various medical conditions. Moreover, expanding facilities attracts investments from both the public and private sectors, supports research, and fosters collaboration between pharmaceutical companies and healthcare institutions, which accelerates the discovery and development of new drugs.

Restraint:

Rising development costs

The process of bringing a new drug from discovery to market approval is capital-intensive, encompassing preclinical studies, extensive clinical trials, and regulatory compliance. These expenses include research, personnel, infrastructure, and compliance with rigorous safety and efficacy standards. The financial burden of these expenses may deter investment in potentially lethal drug candidates and restrict access to advanced therapies, ultimately hindering the field's advancement as well as delaying the release of novel treatments for patients.

Opportunity:

Integration of digital health and AI

AI and digital health technologies enable pharmaceutical researchers to process vast datasets, accelerating the identification of potential drug candidates and predicting their behaviour in biological systems. Machine learning algorithms can analyse molecular structures and identify drug-target interactions, streamlining the lead optimisation process. These technologies also support remote patient monitoring and real-world evidence generation, improving drug safety and efficacy assessments. The synergy between AI and digital health not only expedites drug discovery but also holds the promise of more personalised and effective therapies, attracting substantial investment and innovation in the pharmaceutical industry. Thus, these technologies are propelling market growth.

Threat:

High failure rates

The majority of potential medication combinations do not reach the market because of safety issues, ineffectiveness, or unexpected adverse effects. The drug development process is plagued with uncertainty. Moreover, these failures result in substantial financial losses for pharmaceutical companies and can deter investment in research. The extensive time and resources invested in unsuccessful drugs can hinder innovation and limit the availability of novel therapies, ultimately compromising the industry's ability to address unmet medical needs and improve patient outcomes.

COVID-19 Impact

The COVID-19 pandemic has had a significant impact on the medicinal chemistry market for drug discovery. While it accelerated research for COVID-19 treatments and vaccines, it disrupted non-COVID drug development, causing delays and reallocating resources. Lockdowns affected laboratory work and clinical trials. Collaboration and data sharing have increased to expedite research. Regulatory agencies adapted, expediting approvals. The long-term impact includes changes in research priorities, emphasising vaccine development and antiviral therapies, as well as a renewed emphasis on global health security.

The Biologics segment is expected to be the largest during the forecast period

The Biologics segment is estimated to hold the largest share. Biologics are a class of medicinal products derived from biological sources. These complex molecules, such as monoclonal antibodies, proteins, and nucleic acids, are focused on the development of therapeutic drugs. Biologics are designed to target specific disease pathways with high precision, offering effective treatments for various conditions, including autoimmune disorders, cancer, and rare diseases. Moreover, the development of biologics involves intricate medicinal chemistry, genetic engineering, and biotechnology techniques. Biologics have revolutionised healthcare, providing innovative and often life-changing treatment options, and represent a rapidly growing and evolving sector within the pharmaceutical industry.

The Oncology segment is expected to have the highest CAGR during the forecast period

The Oncology segment is anticipated to have lucrative growth during the forecast period. Oncology is the branch of medicine and medical science that focuses on the discovery and development of drugs specifically for the diagnosis, prevention, and treatment of various forms of cancer. It is a critical area of research due to the prevalence and complexity of cancer. Medicinal chemists in the oncology field design and optimise molecules that target cancer cells, disrupt disease pathways, or enhance the body's ability to fight cancer. In addition, these therapies can include traditional chemotherapies, targeted therapies, immunotherapies, and novel approaches, driving continuous innovation to combat one of the world's most challenging health issues

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region plays a vital role in the medicinal chemistry market for drug discovery. It encompasses diverse countries with growing healthcare infrastructure and research capabilities. China, India, Japan, and South Korea are key hubs for pharmaceutical research and production. The region benefits from lower research costs, attracting investment from global pharmaceutical companies. Furthermore, Asia-Pacific offers opportunities for collaborative research, clinical trials, and access to a vast patient population for testing new drugs, making it a dynamic and significant segment of the global medicinal chemistry for drug discovery market.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. In the United States and Canada, which host many leading pharmaceutical and biotechnology companies, renowned research institutions, and robust healthcare infrastructure, North America is a hub for innovation, with a focus on cutting-edge technologies like genomics and biologics. Moreover, the region benefits from strong intellectual property protection, facilitating drug development and commercialization. North America remains at the forefront of drug discovery, often setting global trends and standards in pharmaceutical research and development.

Key players in the market:

Some of the key players in the Medicinal Chemistry For Drug Discovery Market include Eurofins Scientific, WuXi Apptec, Labcorp Drug Development, Charles River, Evotec SE, Charles River, Piramal Pharma Solutions, Certara USA, Pfizer, Inc., Sygnature Discovery Limited, Jubilant Biosys Ltd., Malvern Panalytical Ltd, Taros Chemicals GmbH & Co. KG, Nereid Therapeutics Inc., Genscript Biotech Corporation, BioBlocks, Inc., Domainex, Aurelia Biosciences Ltd., Thermo Fisher Scientific Inc. and Spectris Plc.

Key Developments:

In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. The data from the trial showed that the companies' lead formulations demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.

In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.

In October 2023, Labcorp, a global leader of innovative and comprehensive laboratory services, announced the launch and national availability of its ATN Profile, a blood-based test that combines three, well-researched blood biomarkers to identify and assess biological changes associated with Alzheimer's disease - amyloid plaques, tau tangles and neurodegeneration (ATN) - which can help accelerate the path to diagnosis and intervention.

In October 2023, Labcorp, a global leader of innovative and comprehensive laboratory services, announced that it acquired Baystate Health, Inc.'s outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts..

Processes Covered:

  • Target Selection
  • Candidate Validation
  • Hit-to-Lead Identification
  • Lead Optimization

Designs Covered:

  • Fragment-Based Variation
  • Diversity Oriented Synthesis
  • Structure Based Drug Design
  • Natural Products
  • Chemogenomics
  • Other Designs

Drug Types Covered:

  • Biologics
  • Small Molecules

Therapeutic Areas Covered:

  • Oncology
  • Infectious and Immune System Diseases
  • Neurology
  • Digestive System Diseases
  • Cardiovascular Diseases
  • Other Therapeutic Areas

Regions Covered:

  • Contract Research Organization
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Medicinal Chemistry For Drug Discovery Market, By Process

  • 5.1 Introduction
  • 5.2 Target Selection
  • 5.3 Candidate Validation
  • 5.4 Hit-to-Lead Identification
  • 5.5 Lead Optimization

6 Global Medicinal Chemistry For Drug Discovery Market, By Design

  • 6.1 Introduction
  • 6.2 Fragment-Based Variation
  • 6.3 Diversity Oriented Synthesis
  • 6.4 Structure Based Drug Design
  • 6.5 Natural Products
  • 6.6 Chemogenomics
  • 6.7 Other Designs

7 Global Medicinal Chemistry For Drug Discovery Market, By Drug Type

  • 7.1 Introduction
  • 7.2 Biologics
  • 7.3 Small Molecules

8 Global Medicinal Chemistry For Drug Discovery Market, By Therapeutic Area

  • 8.1 Introduction
  • 8.2 Oncology
  • 8.3 Infectious and Immune System Diseases
  • 8.4 Neurology
  • 8.5 Digestive System Diseases
  • 8.6 Cardiovascular Diseases
  • 8.7 Other Therapeutic Areas

9 Global Medicinal Chemistry For Drug Discovery Market, By End User

  • 9.1 Introduction
  • 9.2 Contract Research Organization
  • 9.3 Academic and Research Institutes
  • 9.4 Pharmaceutical and Biotechnology Companies
  • 9.5 Other End Users

10 Global Medicinal Chemistry For Drug Discovery Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Eurofins Scientific
  • 12.2 WuXi Apptec
  • 12.3 Labcorp Drug Development
  • 12.4 Charles River
  • 12.5 Evotec SE
  • 12.6 Charles River
  • 12.7 Piramal Pharma Solutions
  • 12.8 Certara USA
  • 12.9 Pfizer, Inc.
  • 12.10 Sygnature Discovery Limited
  • 12.11 Jubilant Biosys Ltd.
  • 12.12 Malvern Panalytical Ltd
  • 12.13 Taros Chemicals GmbH & Co. KG
  • 12.14 Nereid Therapeutics Inc.
  • 12.15 Genscript Biotech Corporation
  • 12.16 BioBlocks, Inc.
  • 12.17 Domainex
  • 12.18 Aurelia Biosciences Ltd.
  • 12.19 Thermo Fisher Scientific Inc.
  • 12.20 Spectris Plc

List of Tables

  • Table 1 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Process (2021-2030) ($MN)
  • Table 3 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Target Selection (2021-2030) ($MN)
  • Table 4 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Candidate Validation (2021-2030) ($MN)
  • Table 5 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Hit-to-Lead Identification (2021-2030) ($MN)
  • Table 6 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Lead Optimization (2021-2030) ($MN)
  • Table 7 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Design (2021-2030) ($MN)
  • Table 8 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Fragment-Based Variation (2021-2030) ($MN)
  • Table 9 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Diversity Oriented Synthesis (2021-2030) ($MN)
  • Table 10 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Structure Based Drug Design (2021-2030) ($MN)
  • Table 11 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Natural Products (2021-2030) ($MN)
  • Table 12 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Chemogenomics (2021-2030) ($MN)
  • Table 13 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Other Designs (2021-2030) ($MN)
  • Table 14 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 15 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 16 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 17 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 18 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 19 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Infectious and Immune System Diseases (2021-2030) ($MN)
  • Table 20 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 21 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Digestive System Diseases (2021-2030) ($MN)
  • Table 22 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 23 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 24 Global Medicinal Chemistry For Drug Discovery Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Contract Research Organization (2021-2030) ($MN)
  • Table 26 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 27 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 28 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.